Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis.

A schematic representation showing immunomodulatory therapy to treat NASH: Livers with NASH have dysregulation in β-oxidation and lipid homeostasis, and as a result lipid get accumulated in hepatocytes, which leads to hepatocyte death and inflammation. DCs recruited to NASH livers are proinflammatory with higher JNK-MAPK activation. Targeting these proinflammatory DCs with immunomodulatory liposomes induce alternative/tolerogenic phenotype and improves NASH.Image 2